Загрузка...
Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
INTRODUCTION: Rilpivirine (RPV) is a new once-daily, non-nucleoside, reverse transcriptase inhibitor (NNRTI). In treatment-naïve patients, RPV has shown non-inferior antiviral activity to efavirenz but data in treatment-experienced patients are more limited. We assessed the efficacy and safety of RP...
Сохранить в:
| Опубликовано в: : | J Int AIDS Soc |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
International AIDS Society
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4225255/ https://ncbi.nlm.nih.gov/pubmed/25397540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19796 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|